Document is current

Article History

Received: 20 October 2021

Accepted: 14 July 2022

First Online: 11 August 2022

Declarations

:

: BIOS: The study followed the recommendations of the Declaration of Helsinki. Written informed consent was obtained previously from all participants of the CODAM, LL, LLS, NTR, RS, and PAN biobanks in accordance with the ethical and institutional regulations. The CODAM study was approved by the institutional review board of the Maastricht University. The LL study was approved by the Medical Ethics committee of the University Medical Centre Groningen (METc UMCG) document number METC UMCG LLDEEP: M12.113965. The study protocol for LLS was approved by the Medical Ethical committee of the Leiden University Medical Center (METC-LDD) before the start of the study. The NTR study protocol was approved by Central Ethics Committee on Research Involving Human Subjects of the VU University Medical Center (CCMO), Amsterdam, an Institutional Review Board certified by the US Office of Human Research Protections (IRB number IRB2991 under Federal-wide Assurance-3703; IRB/institute codes, NTR 03–180). The RS was approved by the Medical Ethics Committee of the Erasmus MC (Erasmus MC MERC, registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272–159521-PG). The PAN study was approved by the institutional review board of the University Medical Centre Utrecht.SHIP-Trend: The study followed the recommendations of the Declaration of Helsinki. The medical ethics committee of the University of Greifswald approved the study protocol, and oral and written informed consent was obtained from all study participants.

: Not applicable.

: T.G.R. is now employed part-time by Novo Nordisk outside of this work. The other authors declare that they have no competing interests.